Folic acid fortification and the birth prevalence of congenital heart defect cases in Alberta, Canada

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 97, Issue 8, 2013, Pages 564-570

  Bedard, Tanya ^a   Lowry, R Brian ^a,b,c   Sibbald, Barbara ^a   Harder, Joyce R ^c,d   Trevenen, Cynthia ^b,c   Horobec, Vera ^e   Dyck, John D ^e,f  

^a Alberta Congenital Anomalies Surveillance System   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ALBERTA CHILDREN S HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e Western Canadian Children's Heart Network   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Alberta; Congenital heart defect; Folic acid fortification; Prevention; Public health

Indexed keywords

FOLIC ACID;

AORTA COARCTATION; ARTICLE; BIRTH; CANADA; CONGENITAL HEART MALFORMATION; ENVIRONMENTAL FACTOR; FALLOT TETRALOGY; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE SEPTUM DEFECT; PATENT FORAMEN OVALE; PREVALENCE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

ALBERTA; CONGENITAL HEART DEFECT; FOLIC ACID FORTIFICATION; PREVENTION; PUBLIC HEALTH;

ALBERTA; FEMALE; FOLIC ACID; HEART DEFECTS, CONGENITAL; HUMANS; MATERNAL EXPOSURE; PREVALENCE;

EID: 84881664826     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23162     Document Type: Article

References (49)

1. Alberta Health and Wellness. 2012. Alberta Congenital Anomalies Surveillance System: ninth report 1997-2009. Edmonton. Available at: http://www.health.alberta.ca/documents/congenitalanomalies_Report_9_2012.pdf. Accessed March 28, 2013.
2. Bedard T, Lowry RB, Sibbald B, et al. 2012. Congenital heart defect case ascertainment by the Alberta Congenital Anomalies Surveillance System. Birth Defects Res A Clin Mol Teratol 94:449-458.
3. Botto LD, Lin AE, Riehle-Colarusso T, et al; National Birth Defects Prevention Study. 2007. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol 79:714-727.
4. Botto LD, Lisi A, Bower C, et al. 2006. Trends of selected malformations in relation to folic acid recommendations and fortification: an international assessment. Birth Defects Res A Clin Mol Teratol 76:693-705.
5. Botto LD, Mulinare J, Erickson JD. 2000. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am J Epidemiol 151:878-884.
6. Botto LD, Khoury MJ, Mulinare J, Erickson JD. 1996. Periconeptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics 98:911-917.
7. Bower C, Miller M, Payne J, Serna P. 2006. Folate intake and the primary prevention of non-neural birth defects. Aust N Z J Public Health 30:258-261.
8. Canada Gazette Part II. 1998. Regulations amending the Food and Drug Regulations (1066). 132:3028-3033.
9. Canfield MA, Collins JS, Botto LD, et al; for the National Birth Defects Prevention Network. 2005. Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study. Birth Defects Res A Clin Mol Teratol 73:679-689.
10. Czeizel AE. 1996. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet 62:179-183.
11. Czeizel AE, Dudás I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 24:1832-1835.
12. De Wals P, Tairou F, Van Allen MI, et al. 2008. Spina bifida before and after folic acid fortification in Canada. Birth Defects Res A Clin Mol Teratol 82:622-626.
13. De Wals P, Tairou F, Van Allen MI, et al. 2007. Reduction in neural tube defects after folic acid fortification in Canada. N Engl J Med 357:135-142.
14. Dolk H, Loane M, Abramasky L, et al. 2010. Birth prevalence of congenital heart disease. Epidemiology 21:275-277.
15. Dolk H, Loane M, Garne E, European Surveillance of Congenital Anomalies (EUROCAT) Working Group. 2011. Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. Circulation 123:841-849.
16. French MR, Barr SI, Levy-Milne R. 2003. Folate intakes and awareness of folate to prevent neural tube defects: A survey of women living in Vancouver, Canada. J Am Diet Assoc 103:181-185.
17. Gilboa SM, Salemi JL, Nembhard WN, et al. 2010. Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006. 122:2254-2263.
18. Godwin KA, Sibbald B, Bedard T, et al. 2008. Changes in frequencies of select congenital anomalies since the onset of folic acid fortification in a Canadian birth defect registry. Can J Public Health 99:271-275.
19. Goldmuntz E, Woyciechowski S, Renstrom D, et al. 2008. Variants of folate metabolism genes and the risk of conotruncal cardiac defects. Circ Cardiovasc Genet 1:126-132.
20. Hoffman JIE, Kaplan S. 2002. The incidence of congenital heart disease. J Am Coll Cardiol 39:1890-1900.
21. Honein MA, Paulozzi LJ, Mathews TJ, et al. 2001. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981-2986.
22. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L. 2009. Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ 338:b1673.
23. Junker R, Kotthoff S, Vielhaber H, et al. 2001. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 51:251-254.
24. Kirby ML, Gale TF, Stewart DE. 1983. Neural crest cells contribute to normal aorticopulmonary septation. Science 220:1059-1061.
25. Langlois PH, Marengo LK, Canfield MA, et al. 2011. Time trends in the prevalence of birth defects in Texas 1999-2007: real or artifcatual? Birth Defects Res A Clin Mol Teratol 91:902-917.
26. López-Camelo JS, Castilla EE, Orioli IM, et al. 2010. Folic acid flour fortification: impact on the fequencies of 52 congenital anomaly types in three South American countries. Am J Med Genet Part A 152A:2444-2458.
27. López-Camelo JS, Orioli IM, da Graca Dutra M, et al. 2005. Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet 135A:120-125.
28. Lowry RB, Bedard T, Sibbald B, et al. 2013. Congenital heart defects and major structural noncardiac anomalies in Alberta, Canada, 1995-2002. Birth Defects Res A Clin Mol Teratol 97:79-86.
29. Lupo PJ, Goldmuntz E, Mitchell LE. 2010. Gene-gene interactions in the folate metabolic pathway and the risk of conotruncal heart defects. J Biomed Biotechnol 2010:630940.
30. McBride KL, Fernbach S, Menesses A, et al. 2004. A family-based association study of congenital left-sided heart malformations and 5, 10 methylenetetrahydrofolate reductase. Birth Defects Res A Clin Mol Teratol 70:825-830.
31. McBride KL, Marengo L, Canfield M, et al. 2005. Epidemiology of noncomplex left ventricular outflow tract obstruction malformations (aortic valve stenosis, coarctation of the aorta, hypoplastic left heart syndrome) in Texas, 1999-2001. Birth Defects Res A Clin Mol Tertatol 73:555-561.
32. Medical Research Council Vitamin Study Resarch Group. 1991. Prevention of neural tube defects: results of the medical research council vitamin study. Lancet 338:131-137.
33. Prsa M, Saroli T, Mackie AS, et al. 2009. Birth prevalence of congenital heart disease. Epidemiology 20:466-468.
34. Public Health Agency of Canada. 2008. Folic acid: why all women who could become pregnant should be taking folic acid. Available at: http://www.phac-aspc.gc.ca/fa-af/index-eng.php. Accessed: 27 March 2013.
35. Ray JG. 2004. Folic acid food fortification in Canada. Nutr Rev 62:S35-S39.
36. Reller MD, Strickland MJ, Riehle-Colarusso T, et al. 2008. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 153:807-813.
37. Robbins JM, Tilford JM, Bird TM, et al. 2006. Hospitalizations of newborns with folate-sensitive birth defects before and after fortification of foods with folic acid. Pediatrics 118:906-915.
38. Sayed AR, Bourne D, Pattinson R, et al. 2008. Decline in the prevalence of neural tube defects following folic acid fortification and its cost benefit in South Africa. Birth Defect Res A Clin Mol Teratol 82:211-216.
39. Scanlon KS, Ferencz C, Loffredo CA, et al. 1998. Preconceptional folate intake and malformations of the cardiac outflow tract. Epidemiology 9:95-98.
40. Scheuerle A. 2011. Clinical differentiation of patent foramen ovale and secundum atrial septal defect: a survey of pediatric cardiologists in Dallas, Texas, USA. J Registry Manag 38:4-8.
41. Shakur YA, Garriguet D, Corey P, O'Connor DL. 2010. Folic acid fortification above mandated levels results in a low prevalence of folate inadequacy among Canadians. Am J Clin Nutr 92:818-825.
42. Shaw GM, Carmichael SL, Yang W, Lammer EJ. 2010. Periconceptional nutrient intakes and risks of conotruncal heart defects. Birth Defects Res A Clin Mol Teratol 88:144-151.
43. Shaw GM, O'Malley CD, Wasserman CR, et al. 1995. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 59:536-545.
44. Shuaibi AM, House JD, Sevenhuysen GP. 2008. Folate status of young Canadian women after folic acid fortification of grain products. J Am Diet Assoc 108:2090-2094.
45. Simmons CJ, Mosley BS, Fulton-Bond CA, Hobbs CA. 2004. Birth defects in Arkansas: Is folic acid fortification making a difference? Birth Defects Res A Clin Mol Teratol 70:559-564.
46. Tang LS, Wlodarczyk BJ, Santillano DR, et al. 2004. Developmental consequences of abnormal folate transport during murine heart morphogenesis. Birth Defects Res A Clin Mol Teratol 70:449-458.
47. van Beynum IM, Kapusta L, Bakker MK, et al. 2010. Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: a registry-based case-control study in the northern Netherlands. Eur Heart J 31:464-471.
48. Werler MM, Hayes C, Louik C, et al. 1999. Multivitamin supplementation and risk of birth defects. Am J Epidemiol 150:675-682.
49. Zhu H, Yang W, Lu W, et al. 2012. Gene variants in the Folate-Mediated One-Carbon Metabolism (FOCM) pathway as risk factors for conotruncal heart defects. Am J Med Genet A 158A:1124-1134.